🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  2. Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 40 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  3. Hydrogel of spirulina-derived exosomes.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-induced Esophagitis

    phase 2 small molecule active

    1 trial

  4. Hydrogen Peroxide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Hydroxyproline and Leucine

    Ultragenyx UK Limited

    Hyperoxaluria

    phase 2 small molecule completed

    1 trial

  6. Hyperbaric Oxygen Therapy

    Summit Therapeutics

    TBI Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  7. Hyperpolarized Xe129

    Regeneron UK Limited

    Pulmonary Artery Hypertension

    phase 2 small molecule terminated

    1 trial

  8. IGEV

    Fudan University

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  9. IL-1Ra Kineret®

    United Therapeutics Europe Ltd

    Intracerebral Haemorrhage

    phase 2 small molecule completed

    1 trial

  10. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  11. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  12. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 small molecule active

    1 trial

  13. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    unresectable stage III NSCLC (Non–small-cell lung cancer)

    phase 2 small molecule active

    1 trial

  14. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)

    phase 2 small molecule active

    1 trial

  15. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    oligometastatic hormone sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  16. IMFINZI 50 mg/mL concentrate for solution for infusion., Ampligen

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 small molecule active

    1 trial

  17. IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE , TREMELIMUMAB

    The George Institute

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  18. IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN

    Ningbo Cancer Hospital

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  20. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT

    phase 2 small molecule active

    1 trial

  21. IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutations and Early Stage HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  22. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    The George Institute

    Intermediate stage hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  23. IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Advanced stage intrahepatic biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  24. IMLIFIDASE

    The George Institute

    kidney trasplant

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources